Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We prospectively conducted a multi-center,open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposideplus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC). Materials and Methods: Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patientsreceived cisplatin 75 mg/m2 on day 1 and either docetaxel 75 mg/m2 on day 1 or etoposide 100 mg/m2 on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks. Results: The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm. Conclusion: DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantlyimproved survival and TTP.
Abstract
Purpose: We prospectively conducted a multi-center,open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposide plus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC). Materials and Methods: Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patients received cisplatin 75 mg/m2 on day 1 and either docetaxel 75 mg/m2 on day 1 or etoposide 100 mg/m2 on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks. Results: The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was 5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm. Conclusion: DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantly improved survival and TTP.
참고문헌 (25)
- "Chemotherapy for nonsmallcell lung cancer", pp.1326~8 (1991)
- "Cancer: principlesand practice of oncology. 6th ed.", pp.925~83 (2001), J.B. LippincottCo
- "New chemotherapeutic agents prolongsurvival and improve quality of life in non-small cell lung cancer:a review of the literature and future directions", 4, pp.1087~100 (1998)
- "Chemotherapy vs supportive care in advanced non-small-celllung cancer Results of a meta-analysis of the literature", pp.861~5 (1994)
- "Chemotherapyin non-small cell lung cancer: a meta-analysis usingupdated data on individual patients from 52 randomizedclinical trials", 311, pp.899~909 (1995)
- "Chemotherapy for advancednon-small-cell lung cancer"
- "Mitomycin, ifosfamide, andcisplatin in unresectable non-small-cell lung cancer: effects onsurvival and quality of life.", 17, pp.3188~94 (1999)
- "Chemotherapy of lung cancer", 327, pp.1434~41 (1992)
- "The treatment of non-small cell lung cancer", pp.6 49~59 (1994)
- "Prospective randomized trial of docetaxelversus best supportive care in patients with non-small-cell lungcancer previously treated with platinum-based chemotherapy", 18, pp.2095~103 (2000)
- "Second line chemotherapyfor NSCLC: establishing a gold standard", 38, pp.5~12 (2002)
- "American Society of Clinical Oncology treatmentof unresectable non-small-cell lung cancer guideline:update 2003", 22, pp.330~53 (2004)
- "Phase II study of docetaxel and cisplatin inadvanced non-small-cell lung cancer", 16, pp.1948~53 (1998)
- "First-line treatment ofadvanced non-small-cell lung cancer with docetaxel and cisplatin:a multicenter phase II study", 9, pp.331~4 (1998)
- "phase III studyof docetaxel plus platinum combinations versus vinorelbineplus cisplatin for advanced non-small-cell lung cancer: theTAX 326 Study Group.", 21, pp.3016~24 (2003)
- "Therapy with cisplatin and etoposide for nonsmall-cell lung cancer", pp.3 104~14 (1986)
- "The expanding role of cisplatin in the treatmentof non-small-cell lung cancer", pp.6 10~21 (1989)
- "Phase II trial of sequential VP-16 cisplatin combinationchemotherapy and radiotherapy for locally advanced", pp.131~9 (1991)
- "Prolonged oral etoposide in combination with intravenouscisplatin for advanced non-small cell lung cancer", 31, pp.105~11 (1999)
- "Concurrent chemoradiation therapy with cisplatin andoral etoposide for locally advanced non-small cell lung cancer", 32, pp.682~9 (2000)
- "Consensus on medical treatment ofnon-small cell lung cancer", 38, pp.63~13 (2002)
- "Phase III randomized trial of docetaxel pluscisplatin versus vindesine plus cisplatin in patients with stageIV non-small-cell lung cancer:the Japanese Taxotere LungCancer Study Group", 22, pp.254~61 (2004)
- "Randomized phase III trial of paclitaxelplus carboplatin versus vinorelbine plus cisplatin in the treatmentof patients with advanced non--small-cell lung cancer:a Southwest Oncology Group trial", 19, pp.3210~8 (2001)
- "Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastaticnon-small cell lung cancer", 16, pp.1069~75 (2005)
- "Comparison of four chemotherapy regimens foradvanced non-small-cell lung cancer", 346, pp.92~8 (2002)